Bridgeway Capital Management LLC Buys 69,744 Shares of Pacira BioSciences, Inc. $PCRX

Key Points

• Bridgeway Capital Management LLC increased its stake in Pacira BioSciences by 19.4%, acquiring an additional 69,744 shares, bringing its total ownership to 428,529 shares valued at approximately $10.6 million.
• Several institutional investors have recently made significant changes to their holdings in Pacira BioSciences, with over 99% of the company's stock now owned by institutional entities.
• Analysts have upgraded Pacira BioSciences' ratings, with several firms raising their outlook from "hold" to "buy" ratings, and a consensus price target set at $30.83.

Bridgeway Capital Management LLC boosted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 19.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 428,529 shares of the company's stock after acquiring an additional 69,744 shares during the period. Bridgeway Capital Management LLC owned 0.93% of Pacira BioSciences worth $10,649,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC purchased a new position in shares of Pacira BioSciences in the first quarter worth about $277,000. ProShare Advisors LLC boosted its holdings in Pacira BioSciences by 30.2% in the 4th quarter. ProShare Advisors LLC now owns 16,003 shares of the company's stock worth $301,000 after buying an additional 3,710 shares during the period. GAMMA Investing LLC grew its stake in Pacira BioSciences by 112.8% in the 1st quarter. GAMMA Investing LLC now owns 3,694 shares of the company's stock valued at $92,000 after buying an additional 1,958 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Pacira BioSciences by 3.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock valued at $491,000 after acquiring an additional 794 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its holdings in shares of Pacira BioSciences by 21,458.4% in the fourth quarter. Public Employees Retirement System of Ohio now owns 91,192 shares of the company's stock worth $1,718,000 after acquiring an additional 90,769 shares during the period. Institutional investors own 99.73% of the company's stock.

Analyst Ratings Changes

PCRX has been the topic of several recent analyst reports. Wall Street Zen raised Pacira BioSciences from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Zacks Research upgraded shares of Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 14th. Needham & Company LLC cut their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price objective on the stock in a research report on Friday, July 25th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $30.83.

Pacira BioSciences Stock Performance

NASDAQ:PCRX opened at $27.18 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.91 and a current ratio of 2.38. Pacira BioSciences, Inc. has a fifty-two week low of $12.61 and a fifty-two week high of $27.64. The business has a 50 day moving average price of $23.85 and a 200-day moving average price of $24.58. The firm has a market cap of $1.22 billion, a PE ratio of -9.78 and a beta of 0.42.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.74 EPS for the quarter, beating analysts' consensus estimates of $0.73 by $0.01. The company had revenue of $181.10 million during the quarter, compared to analyst estimates of $183.11 million. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The firm's revenue was up 1.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.96 EPS. Pacira BioSciences has set its FY 2025 guidance at EPS. Equities research analysts predict that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current year.

Insider Activity

In other news, Director Marcelo Bigal sold 4,912 shares of Pacira BioSciences stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $23.67, for a total value of $116,267.04. Following the sale, the director directly owned 11,393 shares in the company, valued at approximately $269,672.31. This trade represents a 30.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.40% of the stock is owned by insiders.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.